Institute for Quality and Efficiency in Health Care: Executive Summaries

The aims of the planned review arose from the wording of the commission by the Federal Joint Committee, as well as from the approval status of exenatide for the treatment of patients with type 2 diabetes mellitus. The following questions were to be answered by the rapid report: In patients with type 2 diabetes mellitus receiving blood-glucose lowering treatment with metformin and/or sulfonylurea, is there a benefit of add-on exenatide versus add-on placebo or no add-on treatment? In patients with type 2 diabetes mellitus receiving blood-glucose lowering treatment with metformin and/or sulfonylurea, is there an additional benefit of add-on exenatide versus add-on active control? The focus of the evaluation was on patient-relevant therapy goals.